---
schema_version: "secwatch.filing_event.v1"
accession: "0001906324-25-000003"
form_type: "8-K"
ticker: "QDEL"
cik: "0001906324"
company_name: "QuidelOrtho Corp"
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T03:59:43.173056+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# QuidelOrtho expects Q4 2024 revenue of $702-707M, above guidance midpoint

## Summary
- Preliminary total revenue $702-707M, in line with prior guidance; non-respiratory $561-563M, respiratory $141-143M.
- CEO states 'positive note' and expects top-line above 2024 guidance midpoint; full results due Feb 12, 2025.
- Company highlights cost-savings initiatives and leadership realignment during fiscal 2024.
- Respiratory revenue ranges reflect lower Q4 demand compared to prior year; Labs segment also in line.

## SEC filing metadata
- accession: 0001906324-25-000003
- form_type: 8-K
- ticker: QDEL
- cik: 0001906324
- company_name: QuidelOrtho Corp
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1906324/000190632425000003/0001906324-25-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1906324/000190632425000003/qdel-20250113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001906324-25-000003
- JSON: https://secwatch.observer/filing/0001906324-25-000003.json
- Plain text: https://secwatch.observer/filing/0001906324-25-000003.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.